Collaboration

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

By

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

Pricing pressure drives pharma collaborations, report says

Pricing pressure drives pharma collaborations, report says

By

The backlash to expensive specialty medications has forced the drug industry to partner up to prove the benefits of their medicines in the real world, according to a PwC analysis.

Five things for pharma marketers to know: Thursday, June 18

Five things for pharma marketers to know: Thursday, June 18

By

Merck settles a marketing lawsuit for $5.9 million; CVS plans to create diagnostic apps; a survey shows advertising agencies plan to keep head count steady for the rest of the year

Lilly moves to bolster its oncology pipeline

Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute signed on to help the drugmaker develop cancer treatments.

Five things for pharma marketers to know: Monday, May 11

Five things for pharma marketers to know: Monday, May 11

By

Mylan weighs Teva takeover; GSK and UNC launch research center and drug company; FDA approves Roche colorectal cancer drug diagnostic

Five things for pharma marketers to know: Tuesday, April 7

Five things for pharma marketers to know: Tuesday, April 7

By

Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

AstraZeneca, Joslin Diabetes Center ink three-year collaboration

The partners will focus on developing treatments for metabolic disorders.

Sanofi lays off 100 at Boston R&D hub

The Paris-based drugmaker has axed 100 oncology and global R&D employees as part of a reorganization effort.

J&J inks Alzheimer's vaccine deal

The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.

J&J subsidiary inks $35M RNA deal

The ISIS Pharmaceuticals collaboration will focus on gastrointestinal autoimmune disorders.

Daiichi increases efforts to break into opioid market

Daiichi increases efforts to break into opioid market

By

The drugmaker is collaborating with Charleston Laboratories in the development and commercialization of hydrocodone products. The deal means Daiichi Sankyo now has two pipeline opiates.

BMS enters two immuno-oncology deals

The drugmaker has paired up with Incyte and CytomyX in two separate deals.

Vieira, Everyday Health team up

Vieira, Everyday Health team up

By

The two-year collaboration leverages health content from Meredith Vieira's Lives project.

GSK stops Phase-II lupus trial

The drugmaker said JAK inhibitor GSK2586184 showed no effect in Phase II and has put an ulcerative colitis test on hold.

Merck: 2014 is the year of the rebuild

Merck: 2014 is the year of the rebuild

By

The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.

Big Pharma puts $250M towards disease collaboration

Ten pharma companies will share money and biomarker research under an NIH collaboration.

Merck, Ablynx ink immunotherapy deal

The two will explore cancer-attacking nanobodies.

Boehringer, Zealand reframe diabetes pact

The companies are changing the key compound.

AstraZeneca, J&J enter cancer collaborations

AstraZeneca, J&J enter cancer collaborations

By

The new deals seek out new strategies to address an expansive category.

OncoMed pairs up with Celgene for $177.25M

OncoMed pairs up with Celgene for $177.25M

By

The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.

Flavor of the week: antibiotics

AstraZeneca and Roche strike antibiotic deals.

Astellas inks neurodegenerative collaboration deal

Monday's announcement builds on a stream of recent R&D relationships.

Business briefs: Healthcare reform, Amgen, Pakistan pharma stance, digital marketing

Despite a possible government standoff, exchanges are coming, as is a proffered rebrand; Amgen signs a university deal in China; Pakistan seeks to rein in pharma; digital marketing is on the rise, research shows

Business briefs: AbbVie, FDA, and health spending projections

AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011

Business briefs: Merck, AbbVie, Roche, plus new FDA device rule

Complete Response letter slows Merck's suggamedex; AbbVie looks for next Humira; Roche drug gets breakthrough label; FDA effort to better track medical devices

Business briefs: Gilead, Boehringer, Rx sample ban

Gilead's Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples

Business briefs: Boehringer Ingelheim, Sanofi, GSK, Teva

BI cancer drug lands breakthrough therapy designation; Sanofi tallies two European MS drug approvals; GSK terminates testing for a Crohn's drug; and Teva joins cancer collaboration

Business briefs: GSK, Roche, Biogen Idec, Forest

FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO

Business briefs: Bristol-Myers Squibb, Zafgen, GSK, Shire

Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.